BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy ...

Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...